Reimbursement discussions for the one-shot retinal disease treatment Luxturna is being delayed in Korea.

According to Dailypharm coverage, Novartis Korea failed to reach an agreement with the National Health Insurance Service on the drug price of uxturna (voretigene neparvovec) for inherited retinal dystrophy (IRD) within the 60-day deadline and will enter into extended negotiations.

This suggests that the two parties involved (government-pharmaceutical company) were unable to reach an opinion regarding finances for the drug.

Although the company had applied for reimbursement of the drug in September 2021, no progress had been made on its listing for a while and wa